TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06722677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNS
Description: An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham VNS
Description: An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve, the actual intensity is 0 mA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke.
Study: NCT06725966

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Epley maneuver
Description: Epley maneuver using a mechanized chair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized Epley maneuver
Description: Personalized Epley maneuver, using a mechanized chair
Study: NCT06725238

Intervention type: OTHER
Intervention: Acute-to-chronic glycemic ratio
Description: This ratio could be related to diabetic foot ulcer
Study: NCT06725563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopically placed lumen-apposing metal stents for the treatment of IBD-strictures
Description: We will apply standard procedures for endoluminal stenting. A therapeutic colonoscope will be advanced through the bowel up until the stricture. A guidewire will be passed through the lumen at the stricture site. LAMS will be used for strictures \&lt;6cm, with stents ranging in size from 10-16mm in diameter and up to 60mm in length. The stent will be deployed across the stricture with the assistance of endoscopic and fluoroscopic imaging. Individuals will undergo a repeat colonoscopy in 1-3 months to remove the stent.
Study: NCT06726512

Intervention type: DEVICE
Group type: OTHER
Intervention: XEOS AURA 10
Description: Surgery is performed according to standard of care. Directly after surgery, the surgical specimen is taken outside the operation theatre in a dedicated imaging room at the Department of Nuclear Medicine where high-resolution PET-CT imaging of the surgical specimen is performed.
Study: NCT06725524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JMT601
Description: intravenous infusion on day 1 once a week
Study: NCT06726746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: . Using the following settings with the internal handpiece: square pattern with Deep Mode, fractional density of 5% and energy level of 50 mJ and fluence of 283 J/cm2. The handpiece will be inserted into the vagina (up to 10 cm) The handpiece will be positioned with contact to the vagina and will be rotated to apply 12 pulses at each 1-cm marking (application of laser energy at 3-10-cm depths) until the distal end of the vaginal probe reaches the introitus.~The laser application will be performed on an outpatient basis without local anesthesia in outpatient clinic.
Study: NCT06726538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Autologous, adipose-derived mesenchymal stem cells
Description: Patients in group A will receive two infusions of autologous, adipose-derived mesenchymal stem cells at day 0 and day 90 ± 14 at a dose of 10\^6 cells/kg.~Autologous, adipose-derived mesenchymal stem cells used in this study were harvested from autologous fat tissue through an enzyme method and expanded using our in-house optimized serum-free and xeno-free culture under a physiological oxygen concentration of 5%. For clinical use, cells at passage 3 will be harvested in 100 mL Ringer's lactate. Therapeutic ASC products must pass the following releasing criteria: (1) negative for bacteria, fungi and mycoplasma; (2) more than 90% viability; (3) expression of more than 95% positivity for CD105, CD73, and CD90 and less than 2% positivity for CD45, CD34, CD11b, CD19, and HLA-DR; and (4) endotoxin \<5 EU/kg. The patient will be infused with 1x106 cells/kg body weight within 60 minutes via the intravenous route.
Study: NCT06725095

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Matrix Proteins Derivative
Description: Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of non-surgical treatment plus Enamel Matrix Proteins Derivative
Study: NCT06726187

Intervention type: OTHER
Intervention: Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).
Description: Screening questionnaire

Intervention type: OTHER
Intervention: Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).
Description: Screening questionnaire
Study: NCT06725368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCC
Description: PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles. 1 cycle lasts 1 week. The Carboplatin + Paclitaxel administration schedule 3 weeks out of 4, with weekly Cetuximab is authorized.~After 16 cycles: maintenance with Cetuximab 500 mg/m2 every 14 days until unacceptable toxicity or progression or death.
Study: NCT06726161

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RYZ811
Description: Ga-68

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ801
Description: Ac-225
Study: NCT06727396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-508 Tablet
Description: Investigational drug
Study: NCT06582654

Intervention type: DEVICE
Intervention: Sampling
Description: Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study).

Intervention type: DEVICE
Intervention: Sampling
Description: Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study).
Study: NCT06727396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-508 Tablet
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-508 Tablet
Description: Investigational drug
Study: NCT06582654

Intervention type: DEVICE
Intervention: Sampling
Description: Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study).

Intervention type: DEVICE
Intervention: Sampling
Description: Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study).

Intervention type: DEVICE
Intervention: Sampling
Description: Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study).

Intervention type: DEVICE
Intervention: Sampling
Description: Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study).
Study: NCT06582082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: The study group will receive pulmonary rehabilitation
Study: NCT06582082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pursed lip breathing
Description: the control group will stick to pursed lip breathing only
Study: NCT06727396

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo
Study: NCT04406064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific T-cells (VSTs)
Description: VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.
Study: NCT05767359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene Autoleucel
Description: Genetically modified autologous T-cell immunotherapy, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene Autoleucel
Description: Genetically modified autologous T-cell immunotherapy, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting conditioning regimen, nitrogen mustard-derivative, via intravenous infusion per standard care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting conditioning regimen, nitrogen mustard-derivative, via intravenous infusion per standard care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Lymphodepleting conditioning regimen, synthetic purine nucleoside, via intravenous infusion per standard care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Lymphodepleting conditioning regimen, synthetic purine nucleoside, via intravenous infusion per standard care.
Study: NCT04782908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve edge-to-edge repair
Description: Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.
Study: NCT04667403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~* If necessary within 24 hours of the connection if it is a weekly connection,~* Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention.
Study: NCT05111132

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluid challenge (cristalloïd, NaCl 0,9%)
Description: A fluid challenge according to group will be administrated by infusion pump

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluid challenge (cristalloïd, NaCl 0,9%)
Description: A fluid challenge according to group will be administrated by infusion pump
Study: NCT05252533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
Study: NCT05550103

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment
Study: NCT05143970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
Description: Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD).
Study: NCT04727658

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgical thalamotomy on GammaKnife
Description: fractional radiosurgical thalamotomy on an accelerator (3 sessions of 50 Gy at the isocenter )
Study: NCT06241027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve flossing technique
Description: The nerve flossing technique will be perform actively with the participant sitting on the chair. The participant flexed the knee of the target lower extremity backward beside the chair as far back as possible and flexed the neck at the same time, holding both the flexed knee and neck in thisposition for 5 seconds. The participant in turn extended the neck and knee of the target lower extremity, abducted and flexed the hip until pain will feel and did not push beyond that point. This extended position will be hold for 5 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Myofascial release therapy involved the application of a low load, long duration stretch along the line of maximal fascial restriction. Pressure will be applied directly on the skin toward the direction of restriction until resistance of the tissue barrier will felt, Once found , the collagenous barrier will engaged for 90-120 seconds without sliding over the skin or forcing the tissues until the fascia complex started to yield and a sensation of softening will achieved.This stage will be repeated up to 5 times for new barrier until the sensation of tissue restriction during stretching became weaker.
Study: NCT05124665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description.
Study: NCT06201000

Intervention type: DRUG
Intervention: SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
Description: 10 mg of dapagliflozin or empagliflozin
Study: NCT05382026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation during a 6 month resistance training program
Description: 1% chocolate milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplementation during a 6 month resistance training program
Description: Pea-based beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional supplementation during a 6 month resistance training program
Description: Maltodextrin placebo
Study: NCT05565989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBM and II
Description: An initiation to MBM practice (including 4 exercices) and 2 intention implementation exercices are proposed to participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MI
Description: A motivational Interview will be conducted with participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI
Description: A motivational Interview will be conducted with participant.
Study: NCT06231303

Intervention type: GENETIC
Intervention: DNA extraction and PCR amplification
Description: Microbial community genomic DNA extraction from fecal samples will be done using extraction kit in accordance with the manufacturer's instructions. The DNA extract will be checked on a 1% agarose gel, and the DNA concentration and purity will be determined using the NanoDrop 2000 UV-vis spectrophotometer.~The hyper-variable region V3-V4 of the bacterial 16S rRNA gene will be amplified with the primer pair 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTATCTAAT) on a PCR thermocycler. PCR amplification of the 16S rRNA gene will performed as follows:~Initial denaturation at 95 ℃ for 3 min. 27 cycles of denaturing at 95 ℃ for 30 s, annealing at 55 ℃ for 30 s, and extension at 72 ℃ for 45 s.~Final extension step at 72 ℃ for 10 min and incubation at 10 ℃. The PCR product will then be used to quantify different bacterial species in stool samples of patients and controls using real time PCR.

Intervention type: GENETIC
Intervention: DNA extraction and PCR amplification
Description: Microbial community genomic DNA extraction from fecal samples will be done using extraction kit in accordance with the manufacturer's instructions. The DNA extract will be checked on a 1% agarose gel, and the DNA concentration and purity will be determined using the NanoDrop 2000 UV-vis spectrophotometer.~The hyper-variable region V3-V4 of the bacterial 16S rRNA gene will be amplified with the primer pair 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTATCTAAT) on a PCR thermocycler. PCR amplification of the 16S rRNA gene will performed as follows:~Initial denaturation at 95 ℃ for 3 min. 27 cycles of denaturing at 95 ℃ for 30 s, annealing at 55 ℃ for 30 s, and extension at 72 ℃ for 45 s.~Final extension step at 72 ℃ for 10 min and incubation at 10 ℃. The PCR product will then be used to quantify different bacterial species in stool samples of patients and controls using real time PCR.
Study: NCT06132607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preoperative 3D lung reconstruction created with open-source software
Description: Preoperative 3D lung reconstruction created with open-source software 3D Slicer
Study: NCT05489315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positioning with peanut ball
Description: If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional positioning
Description: If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
Study: NCT04965194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: Superficial probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic (LA), and 20 ml of 0.25% bupivacaine will be administered to perform ESP block. LA spread to both cranial and caudal directions will be seen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum plane block
Description: A curved array transducer for the transmuscular QL (TQL) nerve block is placed in the axial plane on the patient's flank just cranial to the iliac crest. The shamrock sign is visualized: The transverse process of vertebra L4 is the stem, whereas the erector spinae posteriorly, QL laterally, and psoas major anteriorly represents the three leaves of the trefoil. The target for injection is the fascial plane between the QL and psoas major muscles. The needle is inserted using an in-plane technique from the posterior end of the transducer through the QL muscle. The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received no regional block
Study: NCT05669079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: 15 mg/m2 daily intravenously for consecutive 3 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord blood
Description: MNC ≥ 3\*108 cells; HLA compatibility ≥ 5/6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor
Description: Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte-colony stimulating factor
Description: Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin / thrombopoietin receptor agonist
Description: Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human thrombopoietin / thrombopoietin receptor agonist
Description: Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
Study: NCT05934292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Single oral dose